Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMT0O7H)

• Drug Name: MK-886 Drug Info
• Synonyms: MK-886; 118414-82-7; MK 886; MK886; 3-(3-(tert-butylthio)-1-(4-chlorobenzyl)-5-isopropyl-1H-indol-2-yl)-2,2-dimethylpropanoic acid; UNII-080626SQ8C; QAOAOVKBIIKRNL-UHFFFAOYSA-N; L-663,536; CHEMBL29097; CHEBI:75390; L 663536; MK-886 (L-663,536); 080626SQ8C; 3-[3-tert-butylsulfanyl-1-[(4-chlorophenyl)methyl]-5-propan-2-ylindol-2-yl]-2,2-dimethylpropanoic acid; 1H-Indole-2-propanoic acid, 1-[(4-chlorophenyl)methyl]-3-[(1,1-dimethylethyl)thio]-Alpha,Alpha-dimethyl-5-(1-methylethyl)- [CAS]; L-663536; SMR000466278

Indication

Disease Entry	ICD 11	Status	REF
Asthma	CA23	Discontinued in Phase 2	[1]

• Cross-matching ID:
  PubChem CID: 3651377
  ChEBI ID: CHEMBL29097
  CAS Number: CAS 118414-82-7
  TTD Drug ID: DMT0O7H

Molecule-Related Drug Atlas

Drug(s) Targeting Arachidonate 5-lipoxygenase (5-LOX)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Zileuton	DMVRIC2	Allergic asthma	CA23.0	Approved	[4]
Diethylcarbamazine	DM1TJ8F	Elephantiasis		Approved	[5]
Silymarin	DMXBYQR	N. A.	N. A.	Phase 4	[6]
3,4-Dihydroxycinnamic Acid	DMVZL26	Thrombocytopenia	3B64	Phase 4	[7]
Avastin+/-Tarceva	DMA86FL	Non-small-cell lung cancer	2C25.Y	Phase 3	[8]
ABT-761	DM3FIC2	Asthma	CA23	Phase 3	[9]
Tenidap	DMHQRYE	Rheumatoid arthritis	FA20	Phase 3	[10]
FPL-62064	DMGF8MZ	Inflammation	1A00-CA43.1	Phase 3	[11]
Flobufen	DMPSG4D	Rheumatoid arthritis	FA20	Phase 3	[12]
Darbufelone	DMYVKM5	Asthma	CA23	Phase 2/3	[13]

Drug(s) Affected By DNA-directed DNA/RNA polymerase mu (POLM)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cyclophosphamide	DM4O2Z7	Advanced cancer	2A00-2F9Z	Approved	[14]
Gentamicin	DMKINJO	Bacteremia	1A73	Approved	[14]
Bortezomib	DMNO38U	Leukemia		Approved	[15]
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[14]
Amphotericin B	DMTAJQE	Acne vulgaris	ED80	Approved	[14]
Estradiol	DMUNTE3	Acne vulgaris	ED80	Approved	[16]
Doxorubicin	DMVP5YE	Acute myelogenous leukaemia	2A41	Approved	[17]
Benzo(a)pyrene	DMN7J43	N. A.	N. A.	Phase 1	[18]
PMID28870136-Compound-52	DMFDERP	N. A.	N. A.	Patented	[19]
COUMARIN	DM0N8ZM	Discovery agent	N.A.	Investigative	[19]

Drug(s) Affected By DNA polymerase kappa (POLK)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[20]
Clorgyline	DMCEUJD	Parkinson disease	8A00.0	Approved	[21]
Paclitaxel	DMLB81S	Breast carcinoma		Approved	[22]
Cupric Sulfate	DMP0NFQ	Fungal infection	1F29-1F2F	Approved	[23]
Irinotecan	DMP6SC2	Adenocarcinoma	2D40	Approved	[24]
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[25]
Doxorubicin	DMVP5YE	Acute myelogenous leukaemia	2A41	Approved	[17]
Guanine	DMIWLJE	N. A.	N. A.	Phase 3	[26]
TAK-243	DM4GKV2	Solid tumour/cancer	2A00-2F9Z	Phase 1	[27]
680C91	DMCDTIG	Solid tumour/cancer	2A00-2F9Z	Preclinical	[28]

Drug(s) Affected By DNA polymerase iota (POLI)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Panobinostat	DM58WKG	Chronic graft versus host disease		Approved	[29]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[30]
Cupric Sulfate	DMP0NFQ	Fungal infection	1F29-1F2F	Approved	[23]
Doxorubicin	DMVP5YE	Acute myelogenous leukaemia	2A41	Approved	[17]
Urethane	DM7NSI0	N. A.	N. A.	Phase 4	[31]
Guanine	DMIWLJE	N. A.	N. A.	Phase 3	[26]
Genistein	DM0JETC	Menopause symptom	GA30.0	Phase 2/3	[32]
Tocopherol	DMBIJZ6	N. A.	N. A.	Phase 2	[33]
PMID28870136-Compound-52	DMFDERP	N. A.	N. A.	Patented	[19]
methyl p-hydroxybenzoate	DMO58UW	Discovery agent	N.A.	Investigative	[34]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Arachidonate 5-lipoxygenase (5-LOX)	TT2J34L	LOX5_HUMAN	Modulator	[2]

Drug Off-Target (DOT)

DOT Name	DOT ID	UniProt ID	Interaction	REF
DNA polymerase iota (POLI)	OTBA4DCE	POLI_HUMAN	Gene/Protein Processing	[3]
DNA polymerase kappa (POLK)	OTKZ38JH	POLK_HUMAN	Gene/Protein Processing	[3]
DNA-directed DNA/RNA polymerase mu (POLM)	OT0SRIP4	DPOLM_HUMAN	Gene/Protein Processing	[3]

References

• [1] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 2655).
• [2] Inhibitory effects of MK-886 on arachidonic acid metabolism in human phagocytes. Br J Pharmacol. 1990 May;100(1):15-20.
• [3] Leukotriene biosynthesis inhibitor MK886 impedes DNA polymerase activity. Chem Res Toxicol. 2013 Feb 18;26(2):221-32. doi: 10.1021/tx300392m. Epub 2013 Jan 31.
• [4] 5-lipoxygenase inhibitor zileuton attenuates ischemic brain damage: involvement of matrix metalloproteinase 9. Neurol Res. 2009 Oct;31(8):848-52.
• [5] Inhibition of leukotriene formation by diethylcarbamazine modifies the acid-base balance in the rabbits with blast injuries of the lungs. Vojnosanit Pregl. 1999 May-Jun;56(3):243-7.
• [6] Anti-inflammatory and anti-arthritic activities of silymarin acting through inhibition of 5-lipoxygenase. Phytomedicine. 2000 Mar;7(1):21-4.
• [7] Phenidone protects the nigral dopaminergic neurons from LPS-induced neurotoxicity. Neurosci Lett. 2008 Nov 7;445(1):1-6.
• [8] Simple analogues of anthralin: unusual specificity of structure and antiproliferative activity. J Med Chem. 1997 Nov 7;40(23):3773-80.
• [9] Treatment with 5-lipoxygenase inhibitor VIA-2291 (Atreleuton) in patients with recent acute coronary syndrome. Circ Cardiovasc Imaging. 2010 May;3(3):298-307.
• [10] The in vitro free radical scavenging activity of tenidap, a new dual cyclo-oxygenase and 5-1ipoxygenase inhibitor. Mediators Inflamm. 1992;1(2):141-3.
• [11] FPL 62064, a topically active 5-lipoxygenase/cyclooxygenase inhibitor. Agents Actions. 1990 Jun;30(3-4):432-42.
• [12] Pharmacological profile of the novel potent antirheumatic 4-(2',4'-difluorobiphenyl-4-yl)-2-methyl-4-oxobutanoic acid. Arzneimittelforschung. 1997 May;47(5):648-52.
• [13] Novel dual cyclooxygenase and lipoxygenase inhibitors targeting hyaluronan-CD44v6 pathway and inducing cytotoxicity in colon cancer cells. Bioorg Med Chem. 2013 May 1;21(9):2551-9.
• [14] Effect of nephrotoxicants and hepatotoxicants on gene expression profile in human peripheral blood mononuclear cells. Biochem Biophys Res Commun. 2010 Oct 15;401(2):245-50. doi: 10.1016/j.bbrc.2010.09.039. Epub 2010 Sep 16.
• [15] The proapoptotic effect of zoledronic acid is independent of either the bone microenvironment or the intrinsic resistance to bortezomib of myeloma cells and is enhanced by the combination with arsenic trioxide. Exp Hematol. 2011 Jan;39(1):55-65.
• [16] Identification of novel low-dose bisphenol a targets in human foreskin fibroblast cells derived from hypospadias patients. PLoS One. 2012;7(5):e36711. doi: 10.1371/journal.pone.0036711. Epub 2012 May 4.
• [17] Bringing in vitro analysis closer to in vivo: studying doxorubicin toxicity and associated mechanisms in 3D human microtissues with PBPK-based dose modelling. Toxicol Lett. 2018 Sep 15;294:184-192.
• [18] Air pollution and DNA methylation alterations in lung cancer: A systematic and comparative study. Oncotarget. 2017 Jan 3;8(1):1369-1391. doi: 10.18632/oncotarget.13622.
• [19] Quantitative phosphoproteomics reveal cellular responses from caffeine, coumarin and quercetin in treated HepG2 cells. Toxicol Appl Pharmacol. 2022 Aug 15;449:116110. doi: 10.1016/j.taap.2022.116110. Epub 2022 Jun 7.
• [20] Integrating multiple omics to unravel mechanisms of Cyclosporin A induced hepatotoxicity in vitro. Toxicol In Vitro. 2015 Apr;29(3):489-501.
• [21] Anti-oncogenic and pro-differentiation effects of clorgyline, a monoamine oxidase A inhibitor, on high grade prostate cancer cells. BMC Med Genomics. 2009 Aug 20;2:55. doi: 10.1186/1755-8794-2-55.
• [22] Effects of paclitaxel on proliferation and apoptosis in human acute myeloid leukemia HL-60 cells. Acta Pharmacol Sin. 2004 Mar;25(3):378-84.
• [23] Physiological and toxicological transcriptome changes in HepG2 cells exposed to copper. Physiol Genomics. 2009 Aug 7;38(3):386-401.
• [24] Clinical determinants of response to irinotecan-based therapy derived from cell line models. Clin Cancer Res. 2008 Oct 15;14(20):6647-55.
• [25] Activation of AIFM2 enhances apoptosis of human lung cancer cells undergoing toxicological stress. Toxicol Lett. 2016 Sep 6;258:227-236.
• [26] Analysis of nucleotide insertion opposite 2,2,4-triamino-5(2H)-oxazolone by eukaryotic B- and Y-family DNA polymerases. Chem Res Toxicol. 2015 Jun 15;28(6):1307-16. doi: 10.1021/acs.chemrestox.5b00114. Epub 2015 Jun 3.
• [27] Inhibiting ubiquitination causes an accumulation of SUMOylated newly synthesized nuclear proteins at PML bodies. J Biol Chem. 2019 Oct 18;294(42):15218-15234. doi: 10.1074/jbc.RA119.009147. Epub 2019 Jul 8.
• [28] Kynurenine Signaling Increases DNA Polymerase Kappa Expression and Promotes Genomic Instability in Glioblastoma Cells. Chem Res Toxicol. 2016 Jan 19;29(1):101-8. doi: 10.1021/acs.chemrestox.5b00452. Epub 2015 Dec 30.
• [29] A transcriptome-based classifier to identify developmental toxicants by stem cell testing: design, validation and optimization for histone deacetylase inhibitors. Arch Toxicol. 2015 Sep;89(9):1599-618.
• [30] Human embryonic stem cell-derived test systems for developmental neurotoxicity: a transcriptomics approach. Arch Toxicol. 2013 Jan;87(1):123-43.
• [31] Ethyl carbamate induces cell death through its effects on multiple metabolic pathways. Chem Biol Interact. 2017 Nov 1;277:21-32.
• [32] A high concentration of genistein down-regulates activin A, Smad3 and other TGF-beta pathway genes in human uterine leiomyoma cells. Exp Mol Med. 2012 Apr 30;44(4):281-92.
• [33] Selenium and vitamin E: cell type- and intervention-specific tissue effects in prostate cancer. J Natl Cancer Inst. 2009 Mar 4;101(5):306-20.
• [34] Transcriptome dynamics of alternative splicing events revealed early phase of apoptosis induced by methylparaben in H1299 human lung carcinoma cells. Arch Toxicol. 2020 Jan;94(1):127-140. doi: 10.1007/s00204-019-02629-w. Epub 2019 Nov 20.